These cells often take effect in both anti-cancer and pro-cancer, and their specific mechanism of regulation and action have not been fully clarified.[25] In addition, there are multiple mechanisms of immune evasion including secretion of other immunoregulatory cytokines such as interleukin-10 (IL10), downregulation of ligands that activate immune cells including major histocompatibility complex (MHC) class I and NKG2D ligands, and expression of ligands that directly inhibit lymphocytes, including T cells.[26–29]. The gene discussed is KLRK1; the disease is cancer.